Drug firm Marksans Pharma Ltd on Thursday (November 13) reported a net profit of ₹98.2 crore for the quarter ended September 2025, up 1.5% from ₹96.7 crore in the same period last year.

Revenue for the quarter grew 12% year-on-year to ₹720 crore from ₹642 crore, reflecting steady business expansion. EBITDA declined 1.7% to ₹144.7 crore from ₹147.2 crore in the year-ago quarter, while the operating margin contracted to 20% from 23% previously.

The company reported a gross profit of ₹411.8 crore, up 7.4% year-on-year, with a gross margin of 57.2%. Earnings per share (EPS) for the quarter stood at ₹2.2.

For the half-year ended September 30, 2025, the company posted operating revenue of ₹1,340.4 crore, up 8.8% from the same period last year. Gross profit for H1 FY26 was ₹770.0 crore, a grow

See Full Page